Spanish Red Biotech Pipeline

MSD

Pembrolizumab/MK-7684 or MK-4830 or MK-5890 or MK-0482

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: KEYMAKER-U01 Master study: A phase 2, Umbrella study with Rolling Arms of Investigational Agents with either Pembrolizumab in combination with Chemotherapy or with Pembrolizumab alone in Patients with Advanced Non-small cell lung cancer (NSCLC)
Phase: 2Phase II in Spain, 1Phase I